Cellyan Biotechnology (HKPD) Current Deferred Revenue (2024 - 2025)
Cellyan Biotechnology's (HKPD) quarterly Current Deferred Revenue came in at $529008.0 in Q3 2025, up 606.5% year-on-year from $74877.0 in Q3 2024, and up 324.88% on a QoQ basis from $124507.0 in Q1 2025.
Cellyan Biotechnology (HKPD) Current Deferred Revenue (2024 - 2025) Analysis & Trends
Cellyan Biotechnology (HKPD) has 2 years of Current Deferred Revenue data on file, last reported at $529008.0 in Q3 2025.
- On a quarterly basis, Current Deferred Revenue rose 606.5% year-over-year to $529008.0 in Q3 2025; TTM through Sep 2025 was $529008.0, a 606.5% increase from a year earlier, with the FY2025 full-year figure at $124507.0, down 34.84% from the prior year.
- Current Deferred Revenue for Q3 2025 stood at $529008.0, up from $124507.0 in the prior quarter.
- Over the last five years, Current Deferred Revenue for HKPD reached as high as $529008.0 in Q3 2025 and fell as low as $74877.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Mckesson | 105.15 Bn | 101.18 Bn | 4.04 Bn |
| 2 | Cencora | 60.58 Bn | 58.40 Bn | 3.59 Bn |
| 3 | Cardinal Health | 53.81 Bn | 49.87 Bn | 2.50 Bn |
| 4 | Henry Schein | 9.71 Bn | 9.57 Bn | 1.07 Bn |
| 5 | Akso Health | 3.28 Bn | 3.28 Bn | - |
| 6 | 111 | 651.73 Mn | 572.63 Mn | 23.58 Mn |
| 7 | Accendra Health | 248.02 Mn | -88.86 Mn | 278.03 Mn |
| 8 | Edap Tms | 230.14 Mn | 215.14 Mn | 8.15 Mn |
| 9 | VitaNova Life Sciences | 11.51 Mn | 11.01 Mn | 316,343.00 |
| 10 | Cellyan Biotechnology | 4.19 Mn | 3.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 529,008.00 |
| Mar 31, 2025 | 124,507.00 |
| Sep 30, 2024 | 74,877.00 |
| Mar 31, 2024 | 191,066.00 |